Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233241 | 0.84 | ALDH1A1 (0.54) | HSPB1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL4232662 | 0.83 | HTT (0.60) | HSPB1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL4236328 | 0.82 | HSPB1 (0.56) | HSPB1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL4233404 | 0.81 | HSPB1 (0.64) | HSPB1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL4688745 | 0.80 | MEN1 (0.47) | HSPB1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL4688753 | 0.80 | MEN1 (0.47) | HSPB1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL30317900 | 0.78 | HSPB1 (0.61) | HSPB1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL5549349 | 0.77 | TTR (0.55) | HSPB1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL4232011 | 0.76 | HSPB1 (0.39) | HSPB1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL307768 | 0.75 | TDP1 (0.61) | ALDH1A1KMT2AMEN1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HSPB1 3146/4885ALDH1A1 4542/4885KMT2A 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.